ETNB

89bio Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website 89bio.com
Employees(FY) 45
ISIN US2825591033

Performance

+1.15%

-0.63%

-4.22%

-5.48%

-28.92%

YTD

-22.39%

Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Advanced Technical Analysis

Technical Analysis of ETNB 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 23 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 38 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ETNB

Stock Rank

Recent News & Updates

2024-12-19 16:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-12-19 03:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-12-04 13:02
Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?(Insider Monkey)
2024-11-29 13:30
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-11-29 00:30
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-26 16:05
89bio to Participate in the 7th Annual Evercore HealthCONx Conference(GlobeNewswire)
2024-11-26 03:05
89bio to Participate in the 7th Annual Evercore HealthCONx Conference(Globenewswire)
2024-11-15 08:05
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024(GlobeNewswire)
2024-11-14 19:05
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024(Globenewswire)
2024-11-12 23:58
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants(GlobeNewswire)
2024-11-12 16:01
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants(GlobeNewswire)
2024-11-12 10:58
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-11-12 03:01
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-11-07 16:05
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates(GlobeNewswire)
2024-11-05 16:05
89bio to Participate in the UBS Global Healthcare Conference(GlobeNewswire)
2024-11-05 03:05
89bio to Participate in the UBS Global Healthcare Conference(Globenewswire)
2024-11-02 12:00
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH(TipRanks)
2024-11-01 13:21
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH(Investor's Business Daily)
2024-10-18 01:01
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings(GuruFocus.com)
2024-10-17 13:05
State Street Corp's Strategic Acquisition in 89bio Inc(GuruFocus.com)
2024-10-15 08:30
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024(GlobeNewswire)
2024-10-14 20:30
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024(Globenewswire)
2024-10-11 16:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-10-11 04:05
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-30 16:05
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference(GlobeNewswire)
2024-09-30 04:05
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference(Globenewswire)
2024-09-19 16:03
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(GlobeNewswire)
2024-09-19 04:03
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-09-16 16:21
89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer(MT Newswires)
2024-09-16 16:05
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer(GlobeNewswire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.